Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

10x Genomics Earnings Call: Key Takeaways

10x Genomics reported 1% revenue growth, driven by spatial consumables and the ATERA launch, while raising full-year guidance despite instrument revenue declines and anticipated gross margin compression from product mix shifts.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthTotal revenue $150.7M, up 1%; spatial consumables up 16%; instruments down 43%.
Mgmt ConfidenceHigh confidence in ATERA demand; production capacity is the primary bottleneck.
Demand VisibilityStrong ATERA orders; demand not a bottleneck; 100+ Catalyst service customers.
Order BookBacklog numbers not shared; management cited 'lots and lots of orders'.
Margin TrendsQ3 gross margin 75%; Q4 expected step-down to low-to-mid 60s.
Op. LeverageOperating expenses decreased to $129M from $132.5M year-over-year.
Pricing PowerFlex Apex has lower per-reaction pricing, creating top-line pressure.
Vol vs PriceSingle-cell growth driven by double-digit reaction volumes; price stabilization noted.
Segment GrowthSpatial consumables outperforming; Chromium instrument revenue declined 23%.
New ClientsTop 20 biopharma companies purchased ATERA; Fred Hutch clinical collaboration announced.
Capex & DebtEnded quarter with $576M cash; no new debt or M&A mentioned.
RegulatoryStanding up internal CLIA lab for 2027 launch; litigation expenses higher.
CommentaryBiology entering AI era; ATERA provides critical data for training models.
New LaunchesATERA commercial shipments started; Centira cloud analysis platform and Flex Apex CRISPR.

Growth

Revenue $150.7M (up 1%); spatial consumables grew 16%; single-cell consumables grew 1%.

Outlook

Raised FY2026 revenue guidance to $625M-$635M; shipping 50 ATERA units by year-end.

Risks

Management avoided specific backlog numbers; gross margins expected to drop to low-to-mid 60s in Q4.

Source

The company's earnings call, NASDAQ: TXG, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

10x Genomics, Inc.: key numbers

Share price
$54.99Close, Nov 16
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from 10x Genomics, Inc.

All →
4:54 PM ET Form 4
Insider Selling

10x Genomics CEO Serge Saxonov Sells $1.95M of Stock

Serge Saxonov, CEO, sold 31,000 shares of 10x Genomics, Inc. at $62.90 a share, worth $1.95M in total on Nov 10, 2026. Shares held after the trade: 1,019,249 (-3.0%).

Value
$1.95M
Shares
31,000
Price
$62.90
Role
CEO
Holding change
-3.0%
Trade date
Nov 10, 2026
4:10 PM ET 8-K
Financial Results

10x Genomics Financial Results

10x Genomics reported Q3 2026 revenue of $150.7 million, a 1% increase year-over-year, and narrowed its net loss to $19.4 million. The company began commercial shipments of its Atera platform and raised its full-year 2026 revenue guidance to a range of $625 million to $635 million.

Term
Q3 2026

“The biggest highlight of the quarter was the start of commercial shipments of Atera. Enthusiasm for the platform has continued to build, and we are incredibly excited to be putting instruments in customers’ hands. We were also encouraged with the results across our broader business, driven by continued strength in consumables.”

Serge Saxonov, Co-founder and CEO of 10x Genomics

“As biology is entering a new era of AI and data maximalism, 10x is positioned incredibly well to benefit and to be the key enabler of progress going forward.”

Serge Saxonov, Co-founder and CEO of 10x Genomics
4:06 PM ET 8-K
Executive Compensation

10x Genomics Executive Compensation

10x Genomics appointed Ansuman Satpathy and Joseph Gilliam to its Board of Directors as Class III directors. Both will receive compensation under the company's Non-Employee Director Compensation Policy, including an annual cash retainer of $60,000 and a one-time restricted stock unit grant valued at $400,000.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.